‼️REGISTRATION CLOSES OCTOBER 17! bit.ly/HSG-Annual-Mee… #HSG2023 Speaker Highlight! Don't miss the opportunity to hear updates from Peter McColgan! Nov. 3rd: Clinical Trial Roundup Nov. 4th: Research Blitz: New & Upcoming Studies #FamilyDay Roche Genentech

Interested in the Generation-HD2 #HDtrial? Dr. Gandhy discusses past findings from Generation-HD1 & details of HD2 now enrolling. Listen TOMORROW on #Help4HDLive @ 1pm PST! blogtalkradio.com/help4hd Listen later: Spotify, iTunes, iHeartRadio, or Blog Talk.

Dr. Rita Gandhy from Genentech (Roche) joined me today to talk about tominersen. Rita shared some great data from Generation-HD1, and we also discussed the clinical their are currently enrolling for - Generation-HD2. Very informative show! tobtr.com/12277168

Unravelling the role of huntingtin: from neurodevelopment to neurodegeneration New scientific commentary by Jordan Schultz, Mohit Neema & Peg Nopoulos tinyurl.com/59emxnff

Results of the phase 3 tominersen GENERATIONHD1 trial are published in NEJM today. So much to be learned from these important data. A huge thanks to the incredible volunteers involved. Read more about it below 👇#Huntingtonsdisease UCL Queen Square Institute of Neurology UK Dementia Research Institute ucl.ac.uk/brain-sciences…

Even when clinical trials don’t go in the hoped for or expected direction, it is still vitally important to share and publish the results. Here is the tominersen article just published in NEJM Group. nejm.org/doi/full/10.10…

Putting it in print: GENERATION HD1 study results published - ift.tt/j826Ov1

A new analysis by Profs Sarah Tabrizi and Edward Wild captures key learnings in using the disease-modifying drug tominersen to treat early-stage Huntington’s disease, following the early stopping of the phase 3 trial. UK Dementia Research Institute UCL Huntington’s Disease Centre UCL Queen Square Institute of Neurology Read more ⬇️ ucl.ac.uk/brain-sciences…

New information has just been published about further findings in the GENERATION-HD1 trial after being halted in 2021. We address these findings as well as dive into the GENERATION-HD2 trial with Dr. Peter McColgan from Roche during our next Breaking Down Barriers.EHDN News

Together with Roche, HSG will work to offer further opportunities to explore and incorporate strategies to successfully identify potential participants for the GENERATION HD2 study focused on the US sites. #HuntingtonsDisease pr.com/press-release/…

Interested in postdoctoral training in fundamental neurobiology in an environment of a world-leading R&D unit, apply to have the best of both worlds! Please RT 1/5

Watch the inspirational #TEDx talk, "The Unlimited Capability of Every Human" by Emmy-award-winning journalist, Charles Sabine. 👉 youtube.com/watch?v=RsUfCK… From war zones to battling #HuntingtonsDisease, his journey offers unparalleled insights into the human spirit.

After “terrific” conference, CHDI Foundation head scientist declares that #HuntingtonsDisease community will “get there” in search for therapies. #CureHDNow Pope Leo XIV President Donald J. Trump HDSA Help4HD Roche PTC Therapeutics uniQure Vertex Pharmaceuticals NIH @NYTimes STAT curehd.blogspot.com/2024/03/huntin…

We’re recruiting a Clinical Research Fellow to work on our #HD-YAS study and exciting trial programme. If you're interested in joining Prof Tabrizi's team UCL Queen Square Institute of Neurology UK Dementia Research Institute then see link below for more details. Closing date 21 April ucl.ac.uk/work-at-ucl/se…

Participate in the #ProjectAWARE 2.0 Survey to help provide the HD research community insight into the knowledge, motivations, and concerns of #HuntingtonsDisease families regarding participating in clinical research. Visit myHDstory.org to get started!

📷Check out the latest discoveries tackling #Parkinson disease: roche.com/stories/redefi… #StrongerTogether #RocheInnovation #InnovationInHealthcare #neuroscience #WorldParkinsonsDay The Science of Parkinson's WPC 2026 Gennaro Pagano

New paper out @BrainComms. Thank you to all brilliant coauthors Rimona Weil Naomi Andrew Lees Peter McColgan Dr Amanda Henrik Zettergerh, Elena Veleva, Rhiannon Laban and Nick Fox! academic.oup.com/braincomms/adv…

More than 185 CAG repeats: a point of no return in Huntington’s disease biology New scientific commentary by Jillian Belgrad & Anastasia Khvorova tinyurl.com/4yu2mkv3

📢 New publication alert! 'Therapeutic validation of MMR-associated genetic modifiers in a human ex vivo model of Huntington disease' by Ferguson et al., 2024 AJHG 🧬 Mike Flower UCL Brain Sciences UCL Queen Square Institute of Neurology sciencedirect.com/science/articl…

New Perspective on #Parkinsons neuroimaging and fluid #biomarkers Angelika Zarkali Rimona Weil nature.com/articles/s4146…